Alternative Causes and Differential Diagnosis

Before an adverse event can be attributed to a drug, competing explanations — the underlying disease, comorbidities, other medicines, and chance — must be considered and, where possible, excluded. The strength of any causality verdict depends heavily on how convincingly these alternative causes have been ruled out.

Definition

Exclusion of alternative causes is the criterion that an adverse event can be more confidently attributed to a drug when the patient's disease, concurrent medications, comorbidities, and chance have been assessed and found unlikely to account for the event, and less confidently when such explanations remain plausible.

Scope

This entry describes the role of differential diagnosis in causality assessment: the kinds of alternative explanations that must be weighed, how their presence lowers the likelihood assigned to the drug, and why incomplete information so often limits the verdict. It is a methodological reference and not guidance for diagnosing any individual patient.

Core questions

• What categories of alternative explanation must be considered for a suspected adverse drug reaction?
• How does the presence of a plausible alternative cause change the likelihood assigned to the drug?
• How is the contribution of concomitant medicines disentangled from the suspected drug?
• Why does missing information about alternatives so often force an inconclusive verdict?

Key concepts

• Differential diagnosis of adverse events
• Underlying disease as a competing cause
• Comorbidities and the natural course of illness
• Concomitant medications and drug-drug interactions
• Confounding by indication
• Chance and coincidence
• Effect of missing information on the verdict

Mechanisms

A causality assessment weighs the suspected drug against every plausible non-drug explanation for the event. The patient's underlying disease or its natural progression may produce the same clinical picture; comorbidities and intercurrent illnesses may intervene; other medicines taken at the same time may be the true agent or may interact with the suspect; and some apparent associations are simply coincidental. Confounding by indication is a particular trap, because the condition prompting the prescription can itself cause the event. When a credible alternative remains, the probability assigned to the drug falls; when alternatives are searched for and excluded, it rises. Because reports frequently lack the data needed to evaluate these competing causes, assessments often default to intermediate or unclassifiable categories (Naranjo 1981; Karch & Lasagna 1977).

Clinical relevance

Judging whether alternative causes have been adequately excluded is essential to interpreting case reports and signals, since an unconsidered competing explanation can inflate or deflate an apparent drug effect. The entry describes how alternatives are weighed as part of evidence appraisal and is not a basis for individual diagnostic or treatment decisions.

Evidence & guidelines

Structured tools incorporate alternative causes explicitly: the Naranjo algorithm asks whether other factors could have produced the reaction (Naranjo 1981), and operational definitions of adverse drug reactions require that the event not be wholly explained by disease or other therapy (Karch & Lasagna 1977; Edwards & Aronson 2000). Systematic appraisal has noted that inconsistent handling of alternative causes is one reason different methods reach different verdicts on the same case (Hutchinson & Lane 1989).

History

Recognising that disease and concurrent treatment can mimic drug effects is intrinsic to clinical diagnosis, and the formalisation of adverse drug reaction assessment in the 1970s made the exclusion of alternative causes an explicit criterion. Karch and Lasagna built it into their operational definition, and Naranjo's 1981 algorithm scored it directly, establishing differential diagnosis as a standing component of causality assessment.

Debates

How aggressively should alternative causes be pursued before attributing an event to a drug?

Demanding exhaustive exclusion of every competing cause can render most spontaneous reports unclassifiable, while accepting weak exclusion inflates apparent drug effects; the inconsistent treatment of alternatives across methods is a recognised source of their disagreement and of limited reproducibility.

Key figures

• Cesar A. Naranjo
• Fred E. Karch
• Louis Lasagna
• I. Ralph Edwards
• Jeffrey K. Aronson

Seminal works

• naranjo-1981
• karch-lasagna-1977

Frequently asked questions

Why must alternative causes be considered in causality assessment?

Because the underlying disease, comorbidities, other medicines, and chance can produce the same event as a drug, the strength of a causality verdict depends on how well these competing explanations have been weighed and excluded.

What is confounding by indication in this context?

It is the situation where the condition that led to the drug being prescribed is itself the cause of the adverse event, so the drug can appear responsible when the underlying illness is the real explanation.